Unlocking precision: the revolutionary impact of 68Ga-PSMA PET/CT in prostate cancer care
In the realm of medical diagnostics, the groundbreaking procedure of 68Ga-PSMA PET/CT has emerged as a game-changer, offering unprecedented insights into the assessment and management of prostate cancer. Its extraordinary precision enables clinicians to visualize prostate cancer at a molecular level. It has revolutionized the diagnosis, staging, and personalized treatment strategies for prostate cancer, ultimately enhancing patient outcomes and reshaping the landscape of prostate cancer care. Below is the review of just some of the latest studies.
Bone scans prove to be less accurate in the initial staging of prostate cancer, often providing overstated results. A recent comparative multicenter study between bone scans and PSMA PET with 167 patients revealed that a staggering 57% of positive bone scans were, in fact, false positives. This indicates that a significant portion of patients identified as having low-volume metastatic disease by bone scans may, in reality, have localized disease. This obviously has implications for the therapeutic decision making but may also negatively impact the psychological well-being of the patients.
A further study aimed to evaluate the additional prognostic value of presurgical PSMA-PET for predicting biochemical recurrence (BCR). In patients with high-risk prostate cancer, using PSMA-PET before surgery indeed helps predict the risk of cancer recurrence more accurately than the existing risk assessment scores CAPRA or postsurgical CAPRA-S. The findings indicate that presurgical PSMA-PET is a valuable tool for better understanding the risk of cancer returning after surgery in these patients.
Yet another study suggests that evaluating tumor-to-salivary gland ratio (PSG score) with the help of 68Ga-PSMA PET can help predict how patients with mCRPC will respond to the 177Lu-PSMA therapy. The higher was the score, the better turned out to be the outcomes of the treatment. Higher PSG scores correlated with stronger PSA decline, longer progression-free and overall survival.
At our clinic, we prioritize advanced diagnostic procedures, such as:
Don’t settle for anything less than the utmost excellence.